Amgen Inc. (AMG)
Summary
AMG Chart
Amgen Touches 52-Week High: Buy, Sell or Hold the Stock?
AMGN's strong growth drivers and promising pipeline support long-term growth, but patent losses, pricing pressure and valuation warrant caution.
Here's Why Amgen (AMGN) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Bet on These Biotech ETFs as Innovation Drives Market-Beating Growth
Biotech ETFs are riding a powerful rally fueled by innovation, obesity drugs and M&A, with three funds offering diversified exposure to growth.
Amgen Inc. (AMG) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Amgen Inc. ever had a stock split?
Amgen Inc. Profile
| Biotechnology Industry | Healthcare Sector | Robert A. Bradway CEO | XHAN Exchange | 031162100 CUSIP |
| US Country | 31,500 Employees | 21 Aug 2026 Last Dividend | 22 Nov 1999 Last Split | 17 Jun 1983 IPO Date |
Overview
Amgen Inc. is a global leader in biotechnology, focusing on the discovery, development, manufacture, and delivery of human therapeutics. The company has a comprehensive portfolio of treatment options targeting various diseases and conditions, ranging from oncology and osteoporosis to cardiovascular diseases and inflammatory disorders. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen serves healthcare providers worldwide, including physicians' clinics, dialysis centers, hospitals, and pharmacies. Its distribution network encompasses pharmaceutical wholesale distributors and direct-to-consumer channels. Amgen’s collaborative efforts extend to several high-profile partnerships with other pharmaceutical giants, including AstraZeneca, Novartis Pharma AG, UCB, Kyowa Kirin Co., Ltd., and BeiGene, Ltd., aiming at the expansion and development of innovative therapies.
Products and Services
- Enbrel - A leading therapy for plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis.
- Otezla - Designed for adults suffering from plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease.
- Prolia - Addresses osteoporosis in postmenopausal women.
- XGEVA - Prevents skeletal-related events.
- Repatha - Reduces the risk of myocardial infarction, stroke, and coronary revascularization.
- Nplate - Treats immune thrombocytopenia.
- KYPROLIS - For relapsed or refractory multiple myeloma patients.
- Aranesp - Addresses a lower-than-normal number of red blood cells and anemia.
- EVENITY - A treatment for osteoporosis in postmenopausal for men and women.
- Vectibix - Treats patients with wild-type RAS metastatic colorectal cancer.
- BLINCYTO - For patients with acute lymphoblastic leukemia.
- TEPEZZA - Treats thyroid eye disease.
- KRYSTEXXA - Addresses chronic refractory gout.
- Additional Products - Amgen also markets Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA, and PROCYSBI, covering a wide range of therapeutic areas.
